SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Authors:
Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT.

Journal:
Adv Drug Deliv Rev

Publication Year: 2021

DOI:
10.1016/j.addr.2021.01.014

PMCID:
PMC7816567

PMID:
33482248

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Adv Drug Deliv Rev

Abbreviation: Adv Drug Deliv Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y. (2023) - Transparency Score: 3/6
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H and 4 more (2023) - Transparency Score: 3/6
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M and 2 more (2022) - Transparency Score: 3/6
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J and 3 more (2022) - Transparency Score: 3/6
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Aldarondo D; Wayne E. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors have no competing interests to declare."

Evidence found in paper:

"We thank JoEllen Barnett for helpful comments and suggestions. Support was received from 10.13039/100005492Stanford University, the Chan Zuckerberg Biohub, 10.13039/100009726Fast Grants, CEND COVID Catalyst Fund, the National Institute Of Allergy And Infectious Diseases of the 10.13039/100000002National Institutes of Health under Award Numbers U19AI111825, U54CA260517 and R01AI139119. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025